Wang Mang-Yuan, Zhu Tao, Yu Guo-Jun, Huo Qiang, Yang Yi-Ning
Clinical Medicine Postdoctoral Research Station, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
Department of Cardiac Surgery, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 Jan;52(1):129-133. doi: 10.12182/20210160108.
To study the effect of cytochrome P-4504F2 ( 4 2) gene polymorphism on the initial dose of warfarin in patients after mechanical heart valve replacement.
We collected 350 patients receiving warfarin after mechanical heart valve replacement from January 2013 to December 2015 in our hospital. According to the international standardized ratio (INR) ≥2 at the initial stage after surgery, the patients were divided into two groups: INR≥2 group and INR<2 group. We selected the blood samples of all the 350 patients with testing the 4 2 gene type of each patient, and analyzed the effect of 4 2 gene polymorphism on the initial dose of warfarin after mechanical heart valve replacement (the average daily dose during hospitalization of patients 5-10 days after mechanical heart valve replacement).
There was no statistical significance in the initial dose of warfarin among patients with different 4 2 genotypes. However, warfarin dose was higher in 4 2 TT genotype than in 4 2 CC carriers ((3.37±0.68) mg vs. (2.94±0.74) mg, <0.05) in INR≥2 group; In patients with the same genotype, the initial dose of warfarin in the 4 2 CC ((4.02±0.58) mg vs. (2.94±0.74) mg) and 4 2 CT genotypes ((4.15±0.88) mg vs. (3.18±0.82) mg) of INR<2 group was higher than that in INR≥2 group ( <0.05). Gender, age, body mass index (BMI), comorbidities (hypertension, diabetes mellitus, coronary heart disease, atrial fibrillation), cytopigment P-450 2C9 ( 2 9), 4 2 and vitamin K peroxide-reductase complex 1 ( 1) gene polymorphism and INR compliance were included in multiple linear regression analysis. The regression equation was as follows: warfarin initial dose (mg) =-8.634+0.352×BMI (kg/m ) +1.102× 4 2 genotype (CC or CT values 1, TT values 2) +2.147× 1 (AA or AG values 1, GG values 2) +1.325×INR ( INR≥2 values 0, INR<2 values 1). The coefficient of determination ( ) of regression equation was 0.431 ( <0.05).
4 2 gene polymorphism may affect the initial dose of warfarin in patients after heart valve replacement, and this effect is also affected by body characteristics and other factors.
研究细胞色素P-450 4F2(CYP4F2)基因多态性对机械心脏瓣膜置换术后患者华法林初始剂量的影响。
收集2013年1月至2015年12月在我院行机械心脏瓣膜置换术后接受华法林治疗的350例患者。根据术后初期国际标准化比值(INR)≥2,将患者分为两组:INR≥2组和INR<2组。选取全部350例患者的血样,检测每位患者的CYP4F2基因类型,分析CYP4F2基因多态性对机械心脏瓣膜置换术后华法林初始剂量(机械心脏瓣膜置换术后5-10天患者住院期间的平均日剂量)的影响。
不同CYP4F2基因型患者的华法林初始剂量无统计学意义。然而,在INR≥2组中,CYP4F2 TT基因型患者的华法林剂量高于CYP4F2 CC携带者((3.37±0.68)mg对(2.94±0.74)mg,P<0.05);在相同基因型患者中,INR<2组的CYP4F2 CC((4.02±0.58)mg对(2.94±0.74)mg)和CYP4F2 CT基因型((4.15±0.88)mg对(3.18±0.82)mg)患者的华法林初始剂量高于INR≥2组(P<0.05)。将性别、年龄、体重指数(BMI)、合并症(高血压、糖尿病、冠心病、心房颤动)、细胞色素P-450 2C9(CYP2C9)、CYP4F2和维生素K过氧化物还原酶复合体1(VKORC1)基因多态性及INR依从性纳入多重线性回归分析。回归方程如下:华法林初始剂量(mg)=-8.634+0.352×BMI(kg/m²)+1.102×CYP4F2基因型(CC或CT值为1,TT值为2)+2.147×VKORC1(AA或AG值为1,GG值为2)+1.325×INR(INR≥2值为0,INR<2值为1)。回归方程的决定系数(R²)为0.431(P<0.05)。
CYP4F2基因多态性可能影响心脏瓣膜置换术后患者的华法林初始剂量,且这种影响还受身体特征等因素的影响。